Departments of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
Departments of Surgery, University of California at Los Angeles, Los Angeles, CA, USA.
Dig Dis Sci. 2019 May;64(5):1110-1118. doi: 10.1007/s10620-018-5404-x. Epub 2018 Dec 17.
As the demand for liver transplantation continues to rise, the scarcity of liver donor grafts has led to the use of extended criteria grafts for liver transplantation in select group of patients. Hepatitis C-seropositive liver grafts have been used primarily in hepatitis C-positive recipients, with studies showing non-inferior outcomes when compared to hepatitis C-negative grafts. Studies suggest that hepatitis C serology status of the donor liver does not influence the patient or graft outcomes in the recipient. These results advocate for offering hepatitis C-positive grafts to all patients awaiting liver transplantation regardless of their hepatitis C status. However, some concerns persist regarding the ethics of potentially introducing a new infection into a patient that could progress to chronic liver disease following liver transplantation. The recent approval of direct-acting antiviral therapy offers a solution to this dilemma, as it has changed the landscape of hepatitis C management by making it a curable disease. In this review, we shall discuss the current evidence regarding the use of hepatitis C-seropositive donor grafts in hepatitis C-positive and hepatitis C-negative patients.
随着肝移植需求的不断增加,肝供体的稀缺性导致在特定患者群体中使用扩展标准的供体进行肝移植。丙型肝炎阳性肝移植物主要用于丙型肝炎阳性受者,研究表明其与丙型肝炎阴性移植物相比具有非劣效性结果。研究表明,供体肝脏的丙型肝炎血清学状态并不影响受者中的患者或移植物结局。这些结果主张向所有等待肝移植的患者提供丙型肝炎阳性移植物,而不论其丙型肝炎状态如何。然而,人们仍然对在患者中引入新感染的潜在风险存在一些担忧,这种感染可能在肝移植后进展为慢性肝病。直接作用抗病毒治疗的最近批准为这一困境提供了一个解决方案,因为它通过使丙型肝炎成为一种可治愈的疾病,改变了丙型肝炎管理的格局。在这篇综述中,我们将讨论关于在丙型肝炎阳性和丙型肝炎阴性患者中使用丙型肝炎血清学阳性供体移植物的现有证据。